Key result
Transcatheter edge-to-edge repair (TEER) is a feasible and safe therapeutic option associated with reduced mitral regurgitation and improved mortality in patients with cardiogenic shock.
Why the study?
Cardiogenic shock with significant mitral regurgitation portends a poor prognosis with limited therapeutic options.
Does transcatheter edge-to-edge repair (TEER) improve hemodynamics and mortality in patients with cardiogenic shock and significant mitral regurgitation?
Does transcatheter edge-to-edge repair (TEER) improve hemodynamics and mortality in patients with cardiogenic shock and significant mitral regurgitation?
TEER represents a feasible and promising therapeutic option that may improve mortality in critically ill patients with cardiogenic shock and significant mitral regurgitation, though randomized trial data is still pending.
Supports TEER consideration in cardiogenic shock with MR; leaves open randomized confirmation of survival benefit.
PURPOSE OF REVIEW: Cardiogenic shock with significant mitral regurgitation portends a poor prognosis with limited therapeutic options. Herein, we review the available evidence regarding the patient characteristics, management, impact of transcatheter edge-to-edge repair (TEER) on hemodynamics, and clinical outcomes of patients with cardiogenic shock and mitral regurgitation. RECENT FINDINGS: Several observational studies and systematic reviews have demonstrated the feasibility and safety of TEER in cardiogenic shock complicated by degenerative or functional mitral regurgitation. Surgical interventions for mitral regurgitation remain limited owing to the risk profile of patients in cardiogenic shock. TEER has been studied in both degenerative and functional mitral regurgitation and remains feasible in the critically ill population. Moreover, TEER is associated with reduction in mitral regurgitation and improvement in-hospital and long-term mortality. SUMMARY: TEER remains a promising therapeutic option in cardiogenic shock complicated by significant mitral regurgitation, but additional research is required to identify patient and procedural characteristics, hemodynamic parameters, and the optimal time for intervention. Moreover, future randomized controlled trials are in progress to evaluate the potential benefit of TEER against medical management in cardiogenic shock and mitral regurgitation.
No takes yet. Share an insight, caveat, or question.
Jung et al. (2022) conducted a review in Mitral regurgitation and cardiogenic shock. Transcatheter edge-to-edge repair (TEER) was evaluated. Transcatheter edge-to-edge repair (TEER) is a feasible and safe therapeutic option associated with reduced mitral regurgitation and improved mortality in patients with cardiogenic shock.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: